Walleye Capital
RNAC icon

Walleye Capital’s Cartesian Therapeutics RNAC Stock Holding History

Walleye Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-43,878
Closed -$316K – 4902
2025
Q4 		$316K Buy
+43,878
New +$355K ﹤0.01% 3266
2020
Q2 		– Sell
-811
Closed -$59K – 912
2020
Q1 		$59K Buy
+811
New +$78.3K 0.01% 671
2019
Q2 		– Sell
-333
Closed -$24K – 1986
2019
Q1 		$24K Buy
+333
New +$21.1K ﹤0.01% 1327

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's RNAC Position: Q1 2026 in Review

Walleye Capital sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 43,878 shares — an estimated $316K sold.

Walleye Capital first reported a position in RNAC in Q1 2019 and held it in 3 quarters. The position peaked at $316K in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Walleye Capital reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 43,878 Cartesian Therapeutics shares in Q1 2026, an estimated $316K.
  • Walleye Capital first reported a position in Cartesian Therapeutics in Q1 2019 and held it in 3 quarters.
  • Walleye Capital's Cartesian Therapeutics position peaked at $316K in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.